Harvard Bioscience, Inc. (HBIO) News
Filter HBIO News Items
HBIO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest HBIO News From Around the Web
Below are the latest news stories about HARVARD BIOSCIENCE INC that investors may wish to consider to help them evaluate HBIO as an investment opportunity.
With 62% ownership of the shares, Harvard Bioscience, Inc. (NASDAQ:HBIO) is heavily dominated by institutional ownersEvery investor in Harvard Bioscience, Inc. ( NASDAQ:HBIO ) should be aware of the most powerful shareholder groups. The... |
10 Stocks Under $10 for 2023In 2023, the only certainty will be uncertainty. |
Harvard Bioscience Announces CFO TransitionHOLLISTON, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced the resignation of Michael Rossi, the Company’s chief financial officer and treasurer, effective December 31, 2022. The Company has appointed Jennifer Cote, the Company’s vice president of global finance, as its interim chief financial officer and treasurer, effective upon Mr. Rossi’s resignation. Mr. Rossi will remain with the Company through May 10, 2023 to provide transi |
President James Green Just Bought 2.3% More Shares In Harvard Bioscience, Inc. (NASDAQ:HBIO)Even if it's not a huge purchase, we think it was good to see that James Green, the President of Harvard Bioscience... |
KeyBanc Reaffirms Their Buy Rating on Harvard Bioscience (HBIO)KeyBanc analyst Paul Knight maintained a Buy rating on Harvard Bioscience (HBIO - Research Report) today and set a price target of $5.00. The company's shares closed yesterday at $2.42.Knight covers the Healthcare sector, focusing on stocks such as Azenta, Harvard Bioscience, and West Pharmaceutical Services. According to TipRanks, Knight has an average return of 1.7% and a 41.96% success rate on recommended stocks. Harvard Bioscience has an analyst consensus of Moderate Buy, with a price target consensus of $5.00.See today’s best-performing stocks on TipRanks >>Based on Harvard Bioscience's latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $29. |
Harvard Bioscience (HBIO) Reports Q3 Loss, Misses Revenue EstimatesHarvard Bioscience (HBIO) delivered earnings and revenue surprises of -120% and 3.85%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock? |
Harvard Bioscience Announces Third Quarter 2022 Financial Results“Fighting through challenging times while building the company and new technologies for the future.”HOLLISTON, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the third quarter ended September 30, 2022. Jim Green, Chairman and CEO, said, "Impacted by a challenging summer, our third quarter revenues were $26.9 million, down 9% from the same quarter prior year. Growth of 6% in our cellular/molecular product reve |
Shareholders in Harvard Bioscience (NASDAQ:HBIO) are in the red if they invested a year agoInvesting in stocks comes with the risk that the share price will fall. Anyone who held Harvard Bioscience, Inc... |
Harvard Bioscience Schedules Third Quarter 2022 Earnings Conference Call for November 8, 2022 at 4:30 PM ETHOLLISTON, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for third quarter ended September 30, 2022 after the market closes on November 8, 2022, and will hold a conference call to discuss the results at 4:30 p.m. Eastern Time. Participants who want to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number. Participants who want to join the audio-only |
When Will Harvard Bioscience, Inc. (NASDAQ:HBIO) Breakeven?With the business potentially at an important milestone, we thought we'd take a closer look at Harvard Bioscience... |